Omega Therapeutics (NASDAQ: OMGA)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-09 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.520 | -0.540 | -0.0200 | ||||
REV | 476.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Omega Therapeutics (NASDAQ: OMGA) through any online brokerage.
Other companies in Omega Therapeutics’s space includes: Outlook Therapeutics (NASDAQ:OTLK), AVEO Pharmaceuticals (NASDAQ:AVEO), Innate Pharma (NASDAQ:IPHA), Graphite Bio (NASDAQ:GRPH) and Jounce Therapeutics (NASDAQ:JNCE).
The latest price target for Omega Therapeutics (NASDAQ: OMGA) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 4.00 expecting OMGA to fall to within 12 months (a possible -20.00% downside). 6 analyst firms have reported ratings in the last year.
The stock price for Omega Therapeutics (NASDAQ: OMGA) is $5 last updated August 15, 2022, 8:00 PM UTC.
There are no upcoming dividends for Omega Therapeutics.
Omega Therapeutics’s Q3 earnings are confirmed for Wednesday, November 9, 2022.
There is no upcoming split for Omega Therapeutics.
Omega Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.